FDA Grants Rare Pediatric Disease Designation For Quoin Pharma’s Lead Asset, QRX003, For Treatment Of Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin
A medicine company got special permission from the government to work on a rare skin disease that hurts kids. This shows doctors think the medicine might really help, which is good news for the company's chances of success.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.